- Home
- AGI vs RVMD Comparison
AGI vs RVMD Comparison
Compare AGI & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGI
- RVMD
- Stock Information
- Founded
- AGI 2003
- RVMD 2014
- Country
- AGI Canada
- RVMD United States
- Employees
- AGI N/A
- RVMD N/A
- Industry
- AGI Precious Metals
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AGI Basic Materials
- RVMD Health Care
- Exchange
- AGI Nasdaq
- RVMD Nasdaq
- Market Cap
- AGI 7.7B
- RVMD 8.7B
- IPO Year
- AGI 1999
- RVMD 2020
- Fundamental
- Price
- AGI $22.71
- RVMD $41.33
- Analyst Decision
- AGI Strong Buy
- RVMD Strong Buy
- Analyst Count
- AGI 4
- RVMD 13
- Target Price
- AGI $23.81
- RVMD $65.15
- AVG Volume (30 Days)
- AGI 2.5M
- RVMD 1.2M
- Earning Date
- AGI 02-19-2025
- RVMD 02-26-2025
- Dividend Yield
- AGI 0.44%
- RVMD N/A
- EPS Growth
- AGI 30.19
- RVMD N/A
- EPS
- AGI 0.69
- RVMD N/A
- Revenue
- AGI $1,346,900,000.00
- RVMD $742,000.00
- Revenue This Year
- AGI $33.20
- RVMD N/A
- Revenue Next Year
- AGI $0.59
- RVMD $1,855.56
- P/E Ratio
- AGI $33.64
- RVMD N/A
- Revenue Growth
- AGI 31.62
- RVMD N/A
- 52 Week Low
- AGI $11.34
- RVMD $28.95
- 52 Week High
- AGI $24.27
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- AGI 61.76
- RVMD 44.66
- Support Level
- AGI $22.15
- RVMD $40.13
- Resistance Level
- AGI $24.27
- RVMD $42.68
- Average True Range (ATR)
- AGI 0.66
- RVMD 1.41
- MACD
- AGI 0.00
- RVMD 0.10
- Stochastic Oscillator
- AGI 52.43
- RVMD 26.42
About AGI Alamos Gold Inc.
Alamos Gold Inc acquires, explores, and produces gold and other precious metals, and operates in two principal geographic areas: Canada and Mexico. The company has three operating mines in North America: Young-Davidson and Island Gold mines operate in Canada and the Mulatos and in Sonora, Mexico. The company generates maximum revenue from the Mulatos mines.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.